Pancreatic Cancer Research

ResearcherUniversity of AntwerpActive in the last 2 years

Evelien Smits

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9255-3435; OpenAlex author ID A5069580321. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 14

  1. IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. Co-author DOI 10.1016/j.omton.2026.201316↗
  2. Short cold atmospheric plasma treatment preserves vascular quiescence in 3D tumor-stroma-endothelial models of pancreatic cancer in vitro and in ovo. Co-author DOI 10.1038/s41698-025-01241-9↗
  3. Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening and Angiogenic Evaluation. Co-author DOI 10.3390/cells14060450↗
  4. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by… Last author DOI 10.1186/s13046-024-03012-z↗
  5. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. Co-author DOI 10.1038/s41698-023-00480-y↗
  6. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pharmthera.2022.108107↗
  7. Cold Atmospheric Plasma Does Not Affect Stellate Cells Phenotype in Pancreatic Cancer Tissue in Ovo. Co-author DOI 10.3390/ijms23041954↗
  8. Physical plasma-derived oxidants sensitize pancreatic cancer cells to ferroptotic cell death. Co-author DOI 10.1016/j.freeradbiomed.2021.02.026↗
  9. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Co-author DOI 10.3390/cancers13050987↗
  10. Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Last author DOI 10.1002/cti2.1165↗
  11. Cold Atmospheric Plasma Treatment for Pancreatic Cancer-The Importance of Pancreatic Stellate Cells. Co-author DOI 10.3390/cancers12102782↗
  12. Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Last author DOI 10.3390/cancers11101597↗
  13. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. Last author DOI 10.1016/j.pharmthera.2018.04.003↗
  14. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Last author DOI 10.18632/oncotarget.18185↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geert Roeyen · 9 shared papers, 2017–2026 · strength 1.29
  2. Christophe Deben · 7 shared papers, 2019–2026 · strength 1.20
  3. Jonas R.M. Van Audenaerde · 8 shared papers, 2017–2026 · strength 1.04
  4. Annemie Bogaerts · 6 shared papers, 2019–2025 · strength 1.02
  5. Angela Privat‐Maldonado · 5 shared papers, 2020–2025 · strength 0.94
  6. Marc Peeters · 8 shared papers, 2017–2024 · strength 0.92
  7. Hans Prenen · 5 shared papers, 2021–2026 · strength 0.81
  8. Ruben Verloy · 4 shared papers, 2020–2025 · strength 0.80
  9. Delphine Quatannens · 4 shared papers, 2020–2025 · strength 0.59
  10. Maxim Le Compte · 2 shared papers, 2023–2024 · strength 0.33
  11. Andreas Domen · 2 shared papers, 2021–2023 · strength 0.26
  12. Timon Vandamme · 2 shared papers, 2021–2023 · strength 0.26
  13. Jinthe Van Loenhout · 3 shared papers, 2017–2020 · strength 0.23
  14. Laura Gehrcken · 1 shared paper, 2026 · strength 0.22
  15. Sofía L. J. Peeters · 1 shared paper, 2023 · strength 0.15
  16. Naresh Kumar · 1 shared paper, 2021 · strength 0.13
  17. Sara R. Zanivan · 1 shared paper, 2021 · strength 0.11
  18. Clare Y. Slaney · 1 shared paper, 2020 · strength 0.09
  19. Atsushi Masamune · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.